Literature DB >> 18977816

BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.

T Foltynie1, B Cheeran, C H Williams-Gray, M J Edwards, S A Schneider, D Weinberger, J C Rothwell, R A Barker, K P Bhatia.   

Abstract

BACKGROUND: Levodopa induced dyskinesias (LID) are a common problem which ultimately limit the effective treatment of patients with Parkinson's disease (PD). There is accumulating evidence that LID develop due to abnormal synaptic plasticity, which is in turn influenced by the release of brain derived neurotrophic factor (BDNF).
METHODS: The influence of a common functional polymorphism of the BDNF gene on the risk of developing dyskinesias in a large cohort of patients with PD (n = 315), who were independently and variably treated with levodopa and/or other dopaminergic treatments, was investigated.
RESULTS: Patients with the met allele of BDNF, associated with lower activity dependent secretion of BDNF, were at significantly higher risk of developing dyskinesias earlier in the course of treatment with dopaminergic agents (hazard ratio for each additional met allele 2.12, p = 0.001), which persisted following adjustment for potential confounding variables.
CONCLUSION: This functional polymorphism may help predict which individuals are most at risk of LID and is consistent with the known actions of BDNF on synaptic plasticity in the striatum.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18977816     DOI: 10.1136/jnnp.2008.154294

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  53 in total

Review 1.  Translating neurobehavioural endpoints of developmental neurotoxicity tests into in vitro assays and readouts.

Authors:  Christoph van Thriel; Remco H S Westerink; Christian Beste; Ambuja S Bale; Pamela J Lein; Marcel Leist
Journal:  Neurotoxicology       Date:  2011-10-12       Impact factor: 4.294

2.  BDNF serum concentrations show no relationship with diagnostic group or medication status in neurodegenerative disease.

Authors:  Josh D Woolley; Eric V Strobl; Wendy B Shelly; Anna M Karydas; R N Robin Ketelle; Owen M Wolkowitz; Bruce L Miller; Katherine P Rankin
Journal:  Curr Alzheimer Res       Date:  2012-09       Impact factor: 3.498

3.  Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.

Authors:  Natalie Kaplan; Aya Vituri; Amos D Korczyn; Oren S Cohen; Rivka Inzelberg; Gilad Yahalom; Evgenia Kozlova; Roni Milgrom; Yael Laitman; Eitan Friedman; Saharon Rosset; Sharon Hassin-Baer
Journal:  J Mol Neurosci       Date:  2014-03-15       Impact factor: 3.444

4.  Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients.

Authors:  Chiara Fabbri; Daniel Souery; Raffaella Calati; Concetta Crisafulli; Armando Chierchia; Diego Albani; Gianluigi Forloni; Alberto Chiesa; Rosalba Martines; Othman Sentissi; Julien Mendlewicz; Giovanni De Girolamo; Alessandro Serretti
Journal:  J Neural Transm (Vienna)       Date:  2014-08-17       Impact factor: 3.575

Review 5.  Dyskinesias and levodopa therapy: why wait?

Authors:  Michele Matarazzo; Alexandra Perez-Soriano; A Jon Stoessl
Journal:  J Neural Transm (Vienna)       Date:  2018-02-10       Impact factor: 3.575

Review 6.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

7.  BDNF in the Aged Brain: Translational Implications for Parkinson's Disease.

Authors:  N M Mercado; T J Collier; C E Sortwell; K Steece-Collier
Journal:  Austin Neurol Neurosci       Date:  2017-09-19

8.  Effects of Fatigue on Balance in Individuals With Parkinson Disease: Influence of Medication and Brain-Derived Neurotrophic Factor Genotype.

Authors:  Michael Baer; Bradley Klemetson; Diana Scott; Andrew S Murtishaw; James W Navalta; Jefferson W Kinney; Merrill R Landers
Journal:  J Neurol Phys Ther       Date:  2018-04       Impact factor: 3.649

9.  BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease.

Authors:  D Luke Fischer; Peggy Auinger; John L Goudreau; Allyson Cole-Strauss; Karl Kieburtz; Jordan J Elm; Mallory L Hacker; P David Charles; Jack W Lipton; Barbara A Pickut; Caryl E Sortwell
Journal:  Neurotherapeutics       Date:  2020-11-19       Impact factor: 7.620

10.  Fast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent, regionally selective bimodal effects on striatal dopamine kinetics in vivo.

Authors:  Rashed Harun; Kristin M Hare; Elizabeth M Brough; Miranda J Munoz; Christine M Grassi; Gonzalo E Torres; Anthony A Grace; Amy K Wagner
Journal:  J Neurochem       Date:  2016-01-13       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.